Gilead to Acquire Ouro Medicines for $2.175 Billion – Keymed Biosciences Secures $320 Million from CM336 TCE Deal
Keymed Biosciences Inc. (HKG: 2162) announced that its NewCo partner Ouro Medicines has entered into...
Shenzhen Salubris Wins NMPA Approval for SAL0150 – Oral Long-Acting Diabetes/Obesity Drug Targets Weekly Dosing Regimen
Shenzhen Salubris Pharmaceuticals Co., Ltd. (SHE: 002294) announced clinical trial approval from China’s National Medical...
Roche Opens Institute of Human Biology – CHF 1.4 Billion Basel Investment Targets Human Model Systems for Drug Discovery Revolution
Roche (SWX: ROG, OTCMKTS: RHHBY) announced the inauguration of the new research home for the...
Kali Therapeutics Licenses KT501 to Sanofi – $1.23B Deal for Trispecific T-Cell Engager Targets Autoimmune Diseases
Kali Therapeutics announced a licensing agreement with Sanofi (NASDAQ: SNY) for KT501, a novel trispecific...
GSK’s Risvutatug Rezetecan Wins Japan ODD – B7-H3 ADC Targets Small-Cell Lung Cancer with Phase 1 Durable Responses
GlaxoSmithKline (GSK; NYSE: GSK) announced that risvutatug rezetecan (Ris-Rez), a B7-H3-targeted antibody-drug conjugate (ADC), received...
Belief BioMed Partners with Grand Life Sciences on BBM-H803 – AAV Gene Therapy for Hemophilia A Targets Greater China Market
Belief BioMed (“BBM”) and Grand Life Sciences Group Co., Ltd. (HKG: 0512) announced an exclusive...
Hanmi Pharmaceutical Partners with Chongqing Zhongfu – Amlodipine/Losartan Fixed-Dose Combo Targets China Out-of-Hospital Digital Market
Hanmi Pharmaceutical (South Korea) announced a partnership with Chongqing Zhongfu Pharmaceutical Co., Ltd. to jointly...
Sinomune Pharma Licenses Seysara from Almirall – Exclusive China Rights to Tetracycline Acne Antibiotic
Sinomune Pharmaceutical Co., Ltd., a China-based dermatological specialist, announced a licensing agreement with Almirall, S.A....
Chipscreen Biosciences Licenses Epidaza to Nizhpharm – $29M Deal Expands HDAC Inhibitor into Central Asia and Eastern Europe
Shenzhen Chipscreen Biosciences Co., Ltd. (SHA: 688321) announced a licensing agreement with Nizhny Novgorod Chemical...
Tenacia Bio Licenses Ztalmy to Golden Age Health – Bain-Backed CNS Specialist Partners on Rare Epilepsy Drug in China
Tenacia Biopharmaceuticals (Shanghai) Co., Ltd., a Bain Capital-incubated CNS specialist, announced a licensing agreement with...
Formosa Pharmaceuticals Licenses APP13007 to Arrotex – Nanoparticle Ophthalmic Steroid Gains Australia/New Zealand Rights
Formosa Pharmaceuticals (TPE: 6838) announced a licensing agreement with Arrotex Pharmaceuticals Pty Ltd., granting the...
Rapport Therapeutics Licenses RAP-219 to Tenacia Bio – $328M Deal Targets Greater China Epilepsy and Bipolar Markets
Rapport Therapeutics, Inc. (NASDAQ: RAPP) announced a licensing agreement with Tenacia Biopharmaceuticals (Shanghai) Co., Ltd....
LexBio Partners with Hiteck Biopharma – AI-Enabled Drug Discovery Alliance Targets Inflammatory Disease Small Molecules
Suzhou Langrui Biopharmaceutical Co., Ltd. (LexBio), an AI-enabled drug development biotech, announced a strategic partnership...
Chongqing Maile Bio-Pharm Partners with Main Luck Pharma on Hematoporphyrin Commercialization – Photodynamic Therapy Targets Superficial Cancers
Chongqing Maile Bio-Pharm Co. Ltd. and Shenzhen Main Luck Pharmaceuticals Inc. announced a strategic partnership...
Shanghai Pharmaceuticals Licenses MCB-166 Antidepressant from SJTU – Novel Mechanism Drug Candidate Targets Mental Health Pipeline
Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607), China’s pharmaceutical distribution leader, announced a licensing agreement with...
Insilico Medicine Launches PandaClaw – AI Agent Platform Transforms Biological Research with Natural Language Interface
Insilico Medicine (HKG: 3696) announced the launch of PandaClaw, a transformative new feature of its...
Insilico Medicine Partners with ASKA Pharma – AI‑Driven Target Discovery Collaboration Targets Gynecological Diseases
Insilico Medicine (HKG: 3696) announced a strategic drug discovery collaboration with ASKA Pharmaceutical Co., Ltd.,...
Qilu Pharma’s QLS1317 Wins NMPA Approval – First‑in‑Class MSI‑H Targeted Therapy Enters Solid Tumor Clinical Trials
Qilu Pharmaceutical Co., Ltd. announced that its self‑developed Category 1 innovative drug, QLS1317 tablets, has...
NHSA Unveils DRG 3.0 Grouping Scheme Roadmap – Systematic Upgrade Targets 2027 Implementation
China’s National Healthcare Security Administration (NHSA) held a briefing outlining the DRG (Diagnosis‑Related Groups) Grouping...
Biocytogen Partners with Moonlight Bio – Antibody‑Cell Therapy Collaboration Targets Difficult‑to‑Treat Cancers
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (SHA: 688796, HKG: 2315) has entered into a strategic partnership...